Introduction
============

Factors that affect cutaneous melanoma need to be addressed and molecular genetic studies appear promising for a precision/personalized medicine approach ([@b1-ol-0-0-10923]--[@b3-ol-0-0-10923]). A growing body of data indicates that besides exposure to ultraviolet (UV) radiation, especially intermittent sun exposure ([@b4-ol-0-0-10923]), sunburns ([@b4-ol-0-0-10923],[@b5-ol-0-0-10923]), and fair skin ([@b4-ol-0-0-10923]--[@b6-ol-0-0-10923]), other factors including vitamin D ([@b2-ol-0-0-10923],[@b3-ol-0-0-10923],[@b7-ol-0-0-10923]), polychlorinated biphenyls ([@b8-ol-0-0-10923]), host inflammatory responses ([@b9-ol-0-0-10923],[@b10-ol-0-0-10923]), geographical factors ([@b5-ol-0-0-10923],[@b6-ol-0-0-10923],[@b11-ol-0-0-10923],[@b12-ol-0-0-10923]), the lifestyle ([@b11-ol-0-0-10923]--[@b13-ol-0-0-10923]), and genetic background can also play a role ([@b1-ol-0-0-10923]--[@b3-ol-0-0-10923],[@b14-ol-0-0-10923]). Melanoma has a rate of 22.0 in males and 18.3 in females per 100,000/year (standardized for European population) in Italy ([@b15-ol-0-0-10923]), and higher incidence rates (32.5/100,000/year in males; 23.7/100,000/year in females) have been recorded in Friuli Venezia Giulia (FVG) ([@b15-ol-0-0-10923]), a Region located in Northeast Italy at the border with Austria and Slovenia. The incidence of melanoma in Italy shows an increasing trend ([@b15-ol-0-0-10923]), Northeast Italy has the highest prevalence of melanoma ([@b16-ol-0-0-10923]), and the FVG Region has the highest rate of hospitalization for melanoma in Italy ([@b17-ol-0-0-10923]).

The interleukin 1 alpha (IL-1α) and IL-1 beta (IL-1β) cytokines and the specific receptor antagonist (IL-1RA) are components of the interleukin 1 family ([@b18-ol-0-0-10923]). IL-1α and IL-1β are involved in several physiological and pathological diseases ([@b18-ol-0-0-10923],[@b19-ol-0-0-10923]), modulating the immune response to pathogenesis and tissue injuries. Moreover, these cytokines have a role in the promotion of cancer-associated inflammation paradoxically both as protective or favoring cancer/metastasis onset ([@b19-ol-0-0-10923],[@b20-ol-0-0-10923]). IL-1RA neutralizes IL-1α and IL-1β action by binding to the IL-1 receptors (IL-1R type I, IL-1R1 and type II, IL-1R2) without causing any signaling transduction ([@b18-ol-0-0-10923]). This prevents the IL-1α and IL-1β induced cascade of kinases that activates NF-kB and cyclooxygenase-2 (COX-2) following IL-1 (either α or β) binding to IL-1R1 ([@b18-ol-0-0-10923]). The IL-1 family of cytokines and receptors is involved in a broad spectrum of immunological and inflammatory responses including activation of lymphocytes ([@b18-ol-0-0-10923]--[@b22-ol-0-0-10923]). Specifically, IL-1 cytokines promote increased levels of the main chemokine IL-8 (CXCL8) and consequently activate recruitment of neutrophils ([@b23-ol-0-0-10923],[@b24-ol-0-0-10923]). An *in vitro* human cellular study showed that IL-1RA inhibits CXCL8 release ([@b24-ol-0-0-10923]). Interestingly, a recent research in myeloid cells found that inflammasomes/IL-1 pathways induce the expression of the programmed death-ligand 1 (PD-L1) on tumor cells, which is an immune checkpoint molecule used as target of melanoma therapy ([@b25-ol-0-0-10923],[@b26-ol-0-0-10923]). Furthermore, blocking IL-1 receptor with IL-1RA or anti-IL-1R1 antibody inhibits tumor growth and metastasis accompanied by decreased accumulation of myeloid cells and expression of the PD-L1 molecule ([@b25-ol-0-0-10923]).

Currently, inflammation and specific IL-1 targeting as treatment of cancer is an active area of experimental and clinical research ([@b18-ol-0-0-10923],[@b20-ol-0-0-10923],[@b27-ol-0-0-10923]). IL-1 mediated inflammation is proposed to contribute to the development and progression of some cancers including melanoma ([@b28-ol-0-0-10923]). IL-1 appear to act at different levels in tumor initiation and progression, including driving chronic non-resolving inflammation, tumor angiogenesis, activation of the IL-17 pathway, induction of myeloid-derived suppressor cells and macrophage recruitment, invasion and metastasis ([@b20-ol-0-0-10923]). The effects of IL-1 cytokines are pleiotropic so that any shift of the biological balance between agonistic and antagonistic signals has the potential to cause a disease ([@b19-ol-0-0-10923]). Notably, the role of IL-1RA in cancer has been studied in different types of tumors showing effects on survival and progression ([@b18-ol-0-0-10923]--[@b22-ol-0-0-10923]).

Increasing evidence showed that genetic polymorphisms of IL-1 family members can affect susceptibility to disease. Human IL-1RA gene (*IL-1RN*) is located in chromosome 2, specifically 2q13-2q21 ([@b29-ol-0-0-10923],[@b30-ol-0-0-10923]). Current studies and meta-analyses evaluated the role of a variable number of tandem (VNTR) 86-bp repeats located in intron 2 of the *IL-1RN* gene in relation to various diseases and cancers, particularly gastric cancer ([@b31-ol-0-0-10923]--[@b33-ol-0-0-10923]). Specifically, the *IL-1RN* allele 2 (*IL-1RN*\*2, constituted of two 86-bp repeats also denoted as short allele) has been associated with increased cancer risk in heterozygous subjects ([@b33-ol-0-0-10923]). Nonetheless, *IL-1RN* VNTR polymorphism roles in cancer still require further study as inconsistent results have been obtained in cancers of different tissue origins ([@b33-ol-0-0-10923]).

So far, only one German study assessed the role of *IL-1RN* VNTR polymorphism in 97 melanoma patients and 343 controls ([@b34-ol-0-0-10923]). No significant findings were obtained, the heterozygous 1/2 genotype was found in 28.8% of advanced melanoma patients vs. 39.6% of healthy controls; P=0.06 ([@b34-ol-0-0-10923]).

Pathways underlying the relationship of *IL-1RN* VNTR and melanoma currently poses an interesting new challenge in melanoma research ([@b1-ol-0-0-10923],[@b34-ol-0-0-10923]) also by considering the potential roles of IL-1RA in modulating PD-1/PD-L1 ([@b25-ol-0-0-10923]).

Progress in the understanding of melanoma risk factors, genomics, and molecular pathogenesis may drive advances in precision medicine applied to melanoma ([@b1-ol-0-0-10923]--[@b3-ol-0-0-10923],[@b35-ol-0-0-10923],[@b36-ol-0-0-10923]).

In light of these observations, we explored *IL-1RN* VNTR polymorphism and its association with cutaneous malignant melanomas, specifically those with metastatic melanoma (MetM) vs. non-metastatic melanoma (NMetM) and vs. healthy controls.

Materials and methods
=====================

### Population

Enrolment and clinical visits of all study participants were performed at the Udine University-Hospital Dermatology Clinic. Diagnostic procedures were carried out according to routine protocols. The Udine Institutional Ethical Committee approved the study protocol, which was conducted according to the Declaration of Helsinki. All participants were alive during enrolment in the study and signed a written informed consent.

Using a case-control design, the study consecutively enrolled 133 (age range of 31--87 years) unrelated patients (hospitalized or outpatients) of both sexes with documented cutaneous melanoma diagnosis and 382 (age range of 31--87 years) asymptomatic healthy controls of both sexes, which were matched for age and ancestry with melanoma cases. Inclusion criteria for both melanoma cases and healthy controls were as follows: Caucasian resident in FVG Region, at least two Italian grandparents born in FVG Region (or Austro-Hungarian territory before World War I) as described ([@b2-ol-0-0-10923],[@b3-ol-0-0-10923]). Due to the demonstrated association of *IL-1RN* VNTR with high-grade athleticism, athletes were excluded both from melanoma cases and healthy controls as described ([@b37-ol-0-0-10923]). Further, exclusion criteria for healthy controls included the following: any kind of lifelong malignant or benign tumor, first-grade relatives with a history of melanoma, and major chronic diseases, such as autoimmune diseases including type 1 diabetes. Among healthy controls 268 subjects were previously studied ([@b37-ol-0-0-10923]).

Melanoma was diagnosed using immunohistological findings obtained after surgical excision of nevi with clinical and dermoscopic characteristics suggesting the presence of malignancy. Classification of melanoma stages was performed by clinical/histological/radiological findings, as described ([@b38-ol-0-0-10923],[@b39-ol-0-0-10923]), which was our routine in the period of the study whose patient enrollment was completed on December 2017. Inclusion criteria for case-patients comprised only cutaneous not mucosal melanomas. For patients with multiple melanomas, the major melanoma characteristics were accounted for in study analyses according to the histological assessment of major primary tumor (T) grading.

Each participant answered a questionnaire, which was used to collect data on demographic characteristics, medical and family history of melanoma, smoking habits, and history of sunburns as described ([@b2-ol-0-0-10923]). Phototype was assessed by Fitzpatrick criteria ([@b39-ol-0-0-10923]). BMI was determined by weight (kg) divided by squared height (m^2^); BMI \>30 kg/m^2^ was considered an indicator of obesity.

### Genetic analysis of the VNTR IL-1RN polymorphism

VNTR *IL-1RN* polymorphism was determined, as previously described ([@b40-ol-0-0-10923]) after extraction of genomic DNA from ethylenediaminetetraacetic-acid-treated venous blood samples ([@b41-ol-0-0-10923]). The *IL-1RN* intron 2 VNTR polymorphism (rs2234663; also indicated as rs380092) was analyzed using 5′-CTCAGCAACACTCCTAT-3′ and 5′-TCCTGGTCTGCAGGTAA-3′ as primers ([@b37-ol-0-0-10923],[@b40-ol-0-0-10923]). The PCR products of 412-bp (allele 1 corresponding to 4 repeats of the 86-bp region), 240-bp (allele 2, 2 repeats also defined as short allele), 498-bp (allele 3, 5 repeats), 326-bp (allele 4, 3 repeats), 584-bp (allele 5, 6 repeats) were analyzed by electrophoresis on 10% acrylamide gel stained with ethidium bromide ([@b40-ol-0-0-10923]). Alleles with three or more 86-bp repeats were denoted as long (L) alleles ([@b37-ol-0-0-10923]).

### Statistical analysis

Continuous variables were expressed as a mean ± standard deviation, and Mann-Whitney *U* test was performed for comparison. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for categorical variables, and P values for two-sided Pearson\'s chi-squared or Fisher\'s exact test were reported as was appropriate.

P\<0.05 was considered to indicate a statistically significant difference and P≤0.10 indicates a tendency to be significant. Statistical software SPSS for Windows (SPSS Inc., Chicago, IL, USA) was used.

Results
=======

### Study subjects

All 515 (133 cutaneous melanoma patients and 382 healthy controls) study subjects were Italian Caucasian residents in Northeast Italy. Melanoma cases and healthy controls did not differ for age.

### Comparison of VNTR IL-1RN genotypes in cutaneous melanoma patients and healthy controls (as shown in [Table I](#tI-ol-0-0-10923){ref-type="table"})

In all 515 study subjects (data shown in [Table SI](#SD1-ol-0-0-10923){ref-type="supplementary-material"}), the most frequent *IL-1RN* allele was allele 1 (*IL-1RN\**1, frequency was 72.9%), followed by allele 2 (*IL-1RN\**2, frequency was 24.5%) and by allele 3 (*IL-1RN\**3, frequency was 2.5%). The rare heterozygous genotype 1/4 was found in one MetM patient, and 1/5 genotype was found in one NMetM patient, finally, the rare homozygous 3/3 was found in one healthy control.

Homozygous 1/1 genotype was less frequent in melanomas than in healthy control subjects (OR=0.62, P=0.017). Conversely, heterozygous 1/2 genotype was almost twice more frequent in melanomas than in healthy patients (OR=1.84, P=0.003). No differences were observed for 1/3, 2/2, and 2/3 genotypes. The group of all heterozygous genotypes containing the short allele 2 and one of the long alleles 1, 3, 4, 5 (designed in the literature as 2/L genotype) ([@b33-ol-0-0-10923],[@b37-ol-0-0-10923]) had OR=1.66, P=0.002 for melanomas compared with healthy controls. The group including all genotypes containing the short allele 2 (heterozygous 2/L plus homozygous 2/2 genotypes) was more frequent in melanoma patients than in healthy controls (OR=1.53, P=0.036).

As shown in [Table I](#tI-ol-0-0-10923){ref-type="table"}, frequency of allele 1, 2, and 3 did not significantly differ between melanoma and healthy groups, although carriers of allele 1 were slightly less frequent among melanoma patients (70.3%) than healthy controls (74.3%), OR=0.82, P=0.199, whereas carriers of the allele 2 were slightly more frequent among melanoma patients (26.3%) than healthy controls (23.2%), OR=1.18, P=0.300.

### Comparisons of IL-1RN VNTR genotypes in MetM and NMetM cutaneous melanoma patients and healthy controls (as shown in [Table II](#tII-ol-0-0-10923){ref-type="table"})

The VNTR *IL-1RN* genotypes were not associated with the metastatic grade of cutaneous melanoma as illustrated in [Table II](#tII-ol-0-0-10923){ref-type="table"} by comparison of MetM with NMetM patients.

By comparison of 61 MetM patients with healthy controls, 1/1 genotype was protective (OR=0.58, P=0.047) and 1/2 was at risk (OR=1.77, P=0.042), the group of 2/L genotypes showed a tendency at risk (OR=1.68, P=0.063).

By comparison of 72 NMetM patients with healthy controls, the 1/2 and 2/L genotypes were at risk (OR=1.90, P=0.013, and OR=2.03, P=0.006, respectively).

The frequency of allele 1, 2, and 3 did not differ between groups as shown in [Table II](#tII-ol-0-0-10923){ref-type="table"}.

### Primary demographic and clinical characteristics of melanoma patients and comparison between VNTR IL-1RN 2/L and other remaining genotypes (as shown in [Table III](#tIII-ol-0-0-10923){ref-type="table"})

Main demographic and clinical characteristics of the 133 melanoma patients are described in [Table III](#tIII-ol-0-0-10923){ref-type="table"}. We examined in detail the differences between heterozygous carriers of the short allele 2 (2/L group, n=60) and the other remaining genotypes (non-2/L group, n=73) in melanoma patients. No differences were noted between groups, however, the frequency of patients with a number of body nevi \>50 tended to be higher in 2/L than non-2/L carriers (58.3% vs. 42.5%, OR=1.90, P=0.069).

In a further analysis (data are not shown) by comparison of 2/L carriers with L/L carriers (n=68) among melanoma patients, still non significant differences were noted, however, frequency of patients with a number of body nevi \>50 tended to be higher in 2/L than L/L carriers (58.3% vs. 42.6%, OR=1.88, CI=0.93--3.80, P=0.077).

Complete questionnaire data including body nevi number were available for 114 healthy control subjects; no significant differences were noted for a nevi number \>50 by comparing 2/L vs. all other remaining genotypes (12/40, 30.0% vs. 25/74, 33.8%, OR=0.84, CI=0.37--1.93, P=0.680), and by comparing 2/L vs. L/L (12/40, 30.0% vs. 23/66, 34.8%, OR=0.80, CI=0.34--1.86, P=0.607).

Discussion
==========

IL-1RA has been implicated in oncogenesis as mice deficient in IL-1RA develop the disease in response to carcinogens ([@b42-ol-0-0-10923]). IL-1RA by binding to IL-1R1 strongly modulates the action of IL-1 (IL-1α and IL-1β) cytokines, which in turn can induce expression of hundreds of genes, including themselves (via a positive feedback loop) ([@b43-ol-0-0-10923]).

IL-1RN VNTR polymorphism
========================

*IL-1RN* is considered an important 'hub' gene in melanoma research ([@b1-ol-0-0-10923]). Previous studies found associations of the short *IL-1RN\*2* allele (two 86-bp repeats) with a variety of epithelial-related chronic inflammatory diseases including psoriasis, scleroderma, alopecia areata, lichen sclerosus, systemic lupus erythematosus, and ulcerative colitis ([@b44-ol-0-0-10923]).

The number of 86-bp repeats in the VNTR *IL-1RN* polymorphism, which is located in intron 2, does not alter the encoded amino acid sequence of IL-1RA, but may be of functional significance as the repeated sequences contain putative binding sites for transcription factors ([@b45-ol-0-0-10923],[@b46-ol-0-0-10923]). A general correlation between *IL-1RN\*2* allele and the presence of autoinflammatory disease strongly supports a role of VNTR *IL-1RN* polymorphism in the control of the inflammatory response ([@b46-ol-0-0-10923]).

We observed a general distribution of *IL-1RN* VNTR genotypes (1/1, 54.8%; 1/2, 33.2%; 1/3, 3.5%; 2/2, 6.8%; 2/3, 1.2%; 1/4, 0.2%; 1/5, 0.2% and 3/3, 0.2%) among the 515 Italian study subjects roughly in agreement with other investigations ([@b33-ol-0-0-10923],[@b34-ol-0-0-10923],[@b40-ol-0-0-10923]).

Notably, in our study, nearly twofold higher frequency of 1/2 VNTR *IL-1RN* genotype was observed in melanoma patients (43.6%) compared with healthy controls (29.6%), OR=1.84, P=0.003. This OR value became slightly lower (but still statistically significant) by grouping all heterozygous genotypes containing the short 2 allele and one long allele (2/L group, OR=1.66, P=0.002), and all carriers of allele 2 (2/L+2/2) (OR=1.53, P=0.036). We observed that the 1/2 genotype was still at risk by comparing separately the subgroups of metastatic melanomas (OR=1.77, P=0.042) and non-metastatic melanoma (OR=1.90, P=0.013) with healthy controls. Heterozygous 2/L carriers were at increased risk when comparing NMetM vs. healthy controls (OR=2.03, P=0.006), whereas a tendency was observed comparing MetM vs. healthy controls (OR=1.68, P=0.063).

Homozygous VNTR *IL-1RN* 1/1 carriers were at reduced risk comparing melanoma cases with healthy controls (OR=0.62, P=0.017). The 1/1 genotype was protective for the subgroup of metastatic melanomas (OR=0.58, P=0.047), however, only a tendency for protection was observed for non-metastatic melanomas compared to healthy controls (OR=0.65, P=0.095).

By a further analysis, we demonstrated that among melanoma patients the 1/2 and 2/L genotypes frequencies did not differ between MetM and NMetM patients. The 2/2 genotype was more frequent in MetM (6.6%) than in NMetM (1.4%) patients, however, such difference was not statistically significant (OR=4.98, P=0.179).

Our study shows in detail that among melanoma patients, the 2/L genotypes did not differ from the remaining genotypes for demographic characteristics, gender, known risk factors, staging, location, and deepening of melanoma. However, we observed that among melanomas 58.3% of 2/L carries had more than 50 body nevi vs. 42.5% of non-2/L carriers OR=1.90, P=0.069. This tendency result should be confirmed in enlarged studies. A possible association of 2/L genotype with an increased number of body nevi could explain the higher risk of 2/L carriers for melanoma because an elevated body nevi number is a recognized risk factor for melanoma.

This study is the first investigation of VNTR *IL-1RN* polymorphism in Italian melanoma patients, and the second one on this polymorphism and melanoma after the study of Broer and colleagues ([@b34-ol-0-0-10923]). Broer and colleagues performed a study in aggressive melanomas having stage III or higher (in other words all metastatic melanomas) and 343 healthy controls finding a frequency of allele *IL-1RN*\*1 of 73.2% in melanomas and of 71.7% in healthy controls, a frequency of allele *IL-1RN*\*2 of 23.7% in melanomas and of 28.3% in healthy controls, whereas the rare allele 3 was found in 2 melanoma patients, and allele 4 was found in 4 melanoma patients. Those data are roughly in line with our allele frequency data. However, the German study ([@b34-ol-0-0-10923]) did not observe statistically significant differences between aggressive melanomas and healthy controls for VNTR *IL-1RN* genotypes; indeed the frequency of 1/2 genotype tended to be even lower in aggressive melanomas than controls (28.8% vs. 39.6%, *P*=0.06). At variance, in our Italian melanoma group, the frequency of 1/2 genotype was 1.5-fold higher (43.6%) than in German patients. Such a difference could derive by different ethnic background ([@b33-ol-0-0-10923]) and/or by selection of melanoma cases. Moreover, the high rate of 1/2 genotype in the German healthy controls could be due to different inclusion/exclusion criteria in respect to our study, for example, in our study we excluded high-grade athletes because they have an increased frequency of VNTR 1/2 genotype ([@b37-ol-0-0-10923]).

The 2/L genotype data of our study are consistent with studies relative to other cancers ([@b33-ol-0-0-10923],[@b47-ol-0-0-10923]). The disproportionate levels of IL-1RA could activate balancing elevation of other factors in the complex network of IL-1 family cytokines and receptors that lead to fine tuning of immune response ([@b19-ol-0-0-10923],[@b48-ol-0-0-10923],[@b49-ol-0-0-10923]).

Despite a large number of studies, the association of VNTR *IL-1RN* with cancer still shows some inconsistencies ([@b33-ol-0-0-10923]). The association of the VNTR *IL-1RN* polymorphism with cancer was examined by Zhang and colleagues ([@b33-ol-0-0-10923]) who performed a meta-analysis including 14,854 cases and 19,337 controls from 71 published case-control studies. Genotypic analysis showed significant associations in gastric cancer (2/L vs. L/L, OR=1.22, CI=1.05--1.41). However, in breast cancer, 2/L vs. L/L was protective (OR=0.74, CI=0.58--0.93), whereas in hepatocellular, cervical and lung cancer data were not significant. Moreover, such positive association with cancer was stronger in Asian than in Caucasian population ([@b33-ol-0-0-10923]). The inconsistency is likely caused in part by the differences in the subject ethnicity, sample sizes, disease stages, and cancer types for studies. It is apparent that further studies with large homogeneous patient populations will be needed to validate the association between VNTR *IL-1RN* gene polymorphism and human cancer.

Allele 2 of VNTR IL-1RA polymorphism (*IL-1RN*\*2) is considered to have modulatory effects on inflammatory response, however, evidence on final effects associated to *IL-1RN*\*2 are contradictory ([@b48-ol-0-0-10923],[@b50-ol-0-0-10923],[@b51-ol-0-0-10923]). Evaluation of comprehensive effects of *IL-1RN*\*2 is complicated by the concurrent modulation of the anti-inflammatory IL-1RA and the pro-inflammatory IL-1 cytokine levels ([@b48-ol-0-0-10923],[@b52-ol-0-0-10923]). The presence of the *IL-1RN*\*2 has been associated with enhanced IL-1β production *in vitro* ([@b48-ol-0-0-10923]), and increased inflammatory response ([@b31-ol-0-0-10923],[@b51-ol-0-0-10923]). Indeed, IL-1RA plasma levels are coordinately regulated by both IL-1RA and IL-1beta genes ([@b53-ol-0-0-10923]) indicating a cross-regulation between the receptor antagonist and IL-1 cytokine expression ([@b48-ol-0-0-10923],[@b49-ol-0-0-10923],[@b54-ol-0-0-10923]). Tissue-specific effects are also possible ([@b33-ol-0-0-10923]).

According to some studies the carriers of *IL-1RN*\*2 have higher IL-1RA levels ([@b53-ol-0-0-10923],[@b55-ol-0-0-10923],[@b56-ol-0-0-10923]), and consequently the 2 allele effects could down-regulate IL-1 mediated pro-inflammatory signaling pathways by the IL-1RA blocking of IL-1R1 ([@b37-ol-0-0-10923],[@b57-ol-0-0-10923],[@b58-ol-0-0-10923]). A recent study ([@b59-ol-0-0-10923]) showed that individuals with genotype 2/2 VNTR *IL-1RN* exhibited higher IL-1RA expression compared to 1/2 and 1/1 genotypes. The same study indicated that *IL-1RN*\*2 might be a risk factor for progressive vitiligo ([@b59-ol-0-0-10923]).

On the basis of such evidence, in *IL-1RN*\*2 carrier the increased IL-1RA expression could provoke a reduced anti-tumor immune capacity and could favor the onset of melanoma. On the other hand, a study ([@b28-ol-0-0-10923]) showed that blocking of IL-1R1 by treatment with IL-1R1 neutralizing antibody or IL-1 pathway-specific siRNAs led to growth arrest in IL-1-positive melanoma cells. Furthermore, blocking the IL-1 pathway increased autophagy in IL-1-positive melanoma cells indicating that the endogenous IL-1 system is functional in most human melanoma and interrupting its signaling inhibits the growth of IL-1-positive melanoma cells ([@b28-ol-0-0-10923]).

It appears plausible that a low IL-1-related immune response (due to moderately elevated IL-1RA as in 2/L genotypes) increases the risk to develop melanoma, but, at the same time, does not increase or even could reduce the risk to develop an aggressive tumor. Such a hypothesis would fit with our present findings showing that 2/L genotype increases the risk to develop melanoma, but is not more frequent in metastatic than non-metastatic melanomas. Furthermore, such hypothesis would also fit with Broer *et al* ([@b34-ol-0-0-10923]) data showing a tendency of lower frequency of 2/L in aggressive melanomas than healthy controls.

IL-1R1 receptor activation by IL-1α and/or IL-1β induces an array of factors including IL-1, IL-6 (CXCL6), IL-8 (CXCL8), interferon (IFN) α, β, and γ, defensins, matrix metalloproteinases (MMPs), C-reactive protein, etc ([@b18-ol-0-0-10923],[@b20-ol-0-0-10923],[@b60-ol-0-0-10923]). Thus, the IL-1RA inhibition of IL-1R1 affects several immune factors. It is worth to note that IL-1RA can compete with IL-1 cytokines also for the IL-1R2, which acts as a decoy receptor. Of note, anakinra (a recombinant form of IL-1RA used as an anti-inflammatory drug in certain diseases) or genetic inactivation of the IL-1β-IL-1R1 system can lead to less melanoma growth in mice ([@b18-ol-0-0-10923],[@b28-ol-0-0-10923]).

A recent study ([@b61-ol-0-0-10923]) showed that in MyD88-/- mice and in C57BL/6 mice treated with anakinra the relapse rates of mice subcutaneous B16 melanoma tumor growth significantly increase. This study suggested that IL-1, via its action on neutrophils, promotes the anti-cancer efficacy of ingenol mebutate (a drug approved for the topical treatment of actinic keratoses that could ultimately also find utility in treating skin cancers), with ingenol mebutate treatment causing both IL-1β induction and IL-1α release from keratinocytes ([@b61-ol-0-0-10923]).

Future research should focus on complex gene interactions and biological pathways related to the IL-1 family of cytokines and receptors and melanoma. Improved comprehension of biomolecular immune pathways will support further progress in melanoma management ([@b1-ol-0-0-10923]--[@b3-ol-0-0-10923],[@b33-ol-0-0-10923],[@b36-ol-0-0-10923]).

Study limitations and strengths
===============================

A strong point of our study is the highly defined ethnic background of subjects. This variable is important in genetic studies. Specifically, evidence on ethical and geographical variability of genetic polymorphisms in IL-1 family genes is growing ([@b23-ol-0-0-10923],[@b33-ol-0-0-10923]). Moreover, variability in racial distribution and genetic melanoma susceptibility among (and across) different countries suggests that melanoma studies should be performed in restricted and well-characterized ethnic groups ([@b6-ol-0-0-10923],[@b11-ol-0-0-10923]). On the other hand, our results cannot be generalized to populations with different genetic backgrounds. A strength of this study is detailed clinical data of melanoma patients. Limitations of our study include a limited sample size in subgroups of patients and high CIs for some categorical variables. These limitations could have influenced the non-significant results showed in [Table II](#tII-ol-0-0-10923){ref-type="table"}. Thus, future large-scale studies are necessary to better assess the role of such variables.

More personalized approach to cancer is a challenge of current research ([@b62-ol-0-0-10923],[@b63-ol-0-0-10923]). Personalized boosting of anti-tumor immunity in advanced melanomas is a new promising trend in the treatment of malignant melanoma. Immunotherapy is successful for some patients without relapse or progression, but many patients undergoing therapy have progressive disease ([@b9-ol-0-0-10923],[@b64-ol-0-0-10923],[@b65-ol-0-0-10923]). Thus, a better understanding of immune factors\' modulation contributing to the development of melanoma may increase the likelihood of future improvements in patient management and melanoma prevention by tailored immune modulation modality. IL-1 cytokines and receptors including IL-1RA act in a complex balance, which can both host protect and harm ([@b19-ol-0-0-10923]). Our data highlighted that in terms of *IL-1RN* gene alteration by VNTR in intron 2, IL-1RA homeostasis plays roles in cutaneous melanoma. *IL-1RN* 2/L (mainly constituted by 1/2 genotype) genotype was found associated to susceptibility to cutaneous melanoma, whereas 1/1 was protective. Thus, our findings support an IL-1 family of receptors contribution to the development of malignant melanoma, suggesting the value of genetic screening as an adjuvant of immune strategies for cancer prevention. Future studies should further explore *IL-1RN* polymorphisms for their inclusion in risk models for individualized prevention/susceptibility/prognosis in the practice of precision medicine applied in cutaneous melanoma.

We first suggest that the heterozygous subjects having the short allele *IL-1RN*\*2 are more prone to cutaneous malignant melanoma showing that (innate) immune mechanisms play a role in the susceptibility/pathogenesis of this cancer. Interrelationships of *IL-1RN* 86-bp VNTR with other polymorphisms including those of IL-1β gene (IL-1B) are of interest for future research ([@b40-ol-0-0-10923],[@b53-ol-0-0-10923]). *IL-1RN* may be a candidate gene for melanoma pathogenesis or may possibly be a linked marker to other, as yet undefined, genes. However, it is tempting to speculate that determination of IL-1 family polymorphisms could be used in the future for a personalized preventive treatment of healthy subjects at high risk to develop melanoma and/or for prognostic evaluation. Notably, IL-1RA seems to have roles in PD-L1 regulation, which is a main target of immune therapy for advanced melanoma ([@b25-ol-0-0-10923]). Interestingly, in our study *IL-1RN* 2/L genotype appears to act as a risk factor for melanoma susceptibility independently by conventional risk factors for melanoma, with the possible exception of the elevated presence of nevi. Further investigations are necessary to extend our findings to also examine different ethnic groups ([@b66-ol-0-0-10923]) and to identify biological pathways related to IL-1RA, which influence skin diseases ([@b67-ol-0-0-10923]). It is likely that cancer treatment and management will be supplemented in the future by extensive systematic assessment of DNA pathways ([@b1-ol-0-0-10923],[@b35-ol-0-0-10923],[@b36-ol-0-0-10923]).
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IL-1RA

:   interleukin 1 receptor antagonist

IL-1RN

:   interleukin 1 receptor antagonist gene

VNTR

:   variable number of tandem repeats polymorphism

FVG

:   Friuli Venezia-Giulia

MetM

:   metastatic melanoma

NMetM

:   non-metastatic melanoma

BMI

:   body mass index

TILs

:   tumor infiltrating lymphocytes

###### 

Genotype frequencies of *IL-1RN* VNTR in all 515 study subjects and comparison of 133 patients with melanoma with 382 healthy controls.

  *IL-1RN* VNTR genotype/allele                                       All subjects (n=515) (%)                                   All patients with melanoma (n=133) (%)                     Healthy controls (n=382) (%)                             OR (95% CI)         P-value Melanoma vs. Control
  ------------------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------------------- ------------------- ------------------------------
  1/1                                                                 282 (54.8)                                                 61 (45.9)                                                  221 (57.9)                                               0.62 (0.41--0.92)   0.017
  1/2                                                                 171 (33.2)                                                 58 (43.6)                                                  113 (29.6)                                               1.84 (1.22--2.77)   0.003
  1/3                                                                 18 (3.5)                                                   5 (3.8)                                                    13 (3.4)                                                 1.11 (0.39--3.17)   0.789
  2/2                                                                 35 (6.8)                                                   5 (3.8)                                                    30 (7.9)                                                 0.46 (0.17--1.21)   0.106
  2/3                                                                 6 (1.2)                                                    2 (1.5)                                                    4 (1.0)                                                  1.44 (0.26--7.97)   0.651
  2/L (1/2 and 2/3)^[a](#tfn1-ol-0-0-10923){ref-type="table-fn"}^     177 (34.4)                                                 60 (45.1)                                                  117 (30.6)                                               1.66 (1.24--2.79)   0.002
  1/2 and 2/2 and 2/3 and 2/4                                         212 (41.2)                                                 65 (48.9)                                                  147 (38.5)                                               1.53 (1.03--2.27)   0.036
  1/3 and 2/3 and 3/3^[b](#tfn2-ol-0-0-10923){ref-type="table-fn"}^   25 (4.9)                                                   7 (5.3)                                                    18 (4.7)                                                 1.12 (0.46--2.75)   0.799
  Allele 1                                                            755 (73.3)^[c](#tfn3-ol-0-0-10923){ref-type="table-fn"}^   187 (70.3)^[c](#tfn3-ol-0-0-10923){ref-type="table-fn"}^   568 (74.3)                                               0.82 (0.60--1.11)   0.199
  Allele 2                                                            247 (24.0)                                                 70 (26.3)                                                  177 (23.2)                                               1.18 (0.86--1.63)   0.300
  Allele 3                                                            26 (2.5)^[d](#tfn4-ol-0-0-10923){ref-type="table-fn"}^     7 (2.6)                                                    19 (2.5)^[d](#tfn4-ol-0-0-10923){ref-type="table-fn"}^   1.06 (0.44--2.55)   0.897

Heterozygous subjects containing the short allele 2 and one long allele (1, 3, 4 and 5) are denoted as 2/L according the literature ([@b33-ol-0-0-10923]).

Homozygous genotype 3/3 was present in only one healthy subject.

One metastatic patients had genotype 1/4, and one non-metastatic patient had genotype 1/5.

One healthy subject had genotype 3/3. *IL-1RN*, interleukin-1 receptor antagonist gene; OR, odds ratio; VNTR, variable number tandem repeat.

###### 

Genotype frequencies of *IL-1RN* VNTR comparisons of 61 patients with MetM and 72 patients with NMetM and 382 healthy controls.

  *IL-1RN* VNTR genotype/allele                                      MetM (n=61) (%)                                           NMetM (n=72) (%)                                           OR^[a](#tfn5-ol-0-0-10923){ref-type="table-fn"}^ (95% CI)   P-value^[a](#tfn5-ol-0-0-10923){ref-type="table-fn"}^   OR^[b](#tfn6-ol-0-0-10923){ref-type="table-fn"}^ (95% CI)   P-value^[b](#tfn6-ol-0-0-10923){ref-type="table-fn"}^   OR^[c](#tfn7-ol-0-0-10923){ref-type="table-fn"}^ (95% CI)   P-value^[c](#tfn7-ol-0-0-10923){ref-type="table-fn"}^
  ------------------------------------------------------------------ --------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------- ----------------------------------------------------------- -------------------------------------------------------
  1/1                                                                27 (44.3)                                                 34 (47.2)                                                  0.89 (0.45--1.76)                                           0.733                                                   0.58 (0.34--1.00)                                           0.047                                                   0.65 (0.39--1.08)                                           0.095^[g](#tfn11-ol-0-0-10923){ref-type="table-fn"}^
  1/2                                                                26 (42.6)                                                 32 (44.4)                                                  0.93 (0.47--1.85)                                           0.833                                                   1.77 (1.02--3.07)                                           0.042                                                   1.90 (1.14--3.18)                                           0.013
  1/3                                                                3 (4.9)                                                   2 (2.8)                                                    1.81 (0.29--11.2)                                           0.660                                                   1.47 (0.41--5.31)                                           0.472                                                   0.81 (0.18--3.67)                                           1.000
  2/2                                                                4 (6.6)                                                   1 (1.4)                                                    4.98 (0.54--45.8)                                           0.179                                                   0.82 (0.28--2.42)                                           1.000                                                   0.16 (0.02--1.23)                                           0.043
  2/3                                                                0 (−)                                                     2 (2.8)                                                    0.97 (0.93--1.01)                                           0.500                                                   0.99 (0.98--1.00)                                           1.000                                                   2.70 (0.48--15.0)                                           0.243
  2/L (1/2 and 2/3)^[f](#tfn10-ol-0-0-10923){ref-type="table-fn"}^   26 (42.6)                                                 34 (47.2)                                                  0.83 (0.42--1.65)                                           0.595                                                   1.68 (0.97--2.92)                                           0.063^[g](#tfn11-ol-0-0-10923){ref-type="table-fn"}^    2.03 (1.21--3.38)                                           0.006
  1/2 and 2/2 and 2/3 and 2/4                                        30 (49.2)                                                 35 (48.6)                                                  1.02 (0.52--2.02)                                           0.948                                                   1.55 (0.90--2.66)                                           0.113                                                   1.51 (0.91--2.51)                                           0.108
  1/3 and 2/3 and 3/3                                                3 (4.9)                                                   4 (5.5)                                                    0.88 (0.19--4.09)                                           1.000                                                   1.05 (0.30--3.66)                                           1.000                                                   1.19 (0.39--3.62)                                           0.764
  Allele 1                                                           84^[d](#tfn8-ol-0-0-10923){ref-type="table-fn"}^ (68.9)   103^[e](#tfn9-ol-0-0-10923){ref-type="table-fn"}^ (71.5)   0.88 (0.52--1.49)                                           0.634                                                   0.76 (0.50--1.16)                                           0.201                                                   0.87 (0.58--1.29)                                           0.480
  Allele 2                                                           34 (27.9)                                                 36 (25.0)                                                  1.16 (0.67--2.00)                                           0.596                                                   1.28 (0.83--1.97)                                           0.258                                                   1.10 (0.73--1.67)                                           0.634
  Allele 3                                                           3 (2.5)                                                   4 (2.8)                                                    0.88 (0.19--4.02)                                           1.000                                                   0.99 (0.29--3.39)                                           1.000                                                   1.12 (0.37--3.34)                                           0.774

Comparison between MetM and NMetM.

Comparison between MetM and healthy controls.

Comparison between NMetM and healthy controls.

One metastatic patients had genotype 1/4.

One non-metastatic patient had genotype 1/5.

Heterozygous subjects containing the short allele 2 and one long allele are denoted as 2/L in the literature ([@b33-ol-0-0-10923]).

Significant tendencies. *IL-1RN*, interleukin-1 receptor antagonist gene; MetM, metastatic melanoma; NMetM, non-metastatic melanoma; OR, odds ratio; VNTR, variable number tandem repeat.

###### 

Clinical characteristics of 133 patients with melanoma consecutively enrolled, and comparison between the two genetic subgroups of *IL-1RN* VNTR 2/L genotypes (n=60) and all other genotypes (n=73).

  Characteristics                                  All patients with melanoma (n=133)                         2/L genotype (n=60)                                                                                  Non-2/L genotypes (n=73)                                   OR (CI), 2/L vs. Non-2/L   P-value, 2/L vs. Non-2/L
  ------------------------------------------------ ---------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ---------------------------------------------------------- -------------------------- ------------------------------------------------------
  Age \<50 years, n (%)                            29 (21.8)                                                  13 (21.7)                                                                                            16 (21.9)                                                  0.98 (0.43--2.25)          0.972
  Age at study enrolment, years, mean ± SD         60.8±12.7                                                  61.1±12.9                                                                                            60.7±12.7                                                  --                         0.788^[a](#tfn12-ol-0-0-10923){ref-type="table-fn"}^
  Age at melanoma diagnosis, years, mean ± SD      54.2±13.7                                                  54.4±13.5                                                                                            54.0±14.0                                                  --                         0.781^[a](#tfn12-ol-0-0-10923){ref-type="table-fn"}^
  Time from melanoma diagnosis, years, mean ± SD   6.7±4.1                                                    6.7±4.4                                                                                              6.6±3.9                                                    --                         0.754^[a](#tfn12-ol-0-0-10923){ref-type="table-fn"}^
  Females, n (%)                                   58 (43.6)                                                  26 (43.3)                                                                                            32 (43.8)                                                  0.98 (0.49--1.95)          0.954
  Males, n (%)                                     75 (56.4)                                                  34 (56.7)                                                                                            41 (56.2)                                                  1.02 (0.51--2.03)          0.954
  All grand-parents born in FVG                    96 (72.2)                                                  43 (71.7)                                                                                            53 (72.6)                                                  0.95 (0.45--2.04)          0.905
  BMI, kg/m^2^, mean ± SD                          25.8±3.97                                                  26.1±4.0                                                                                             25.6±4.0                                                   --                         0.643^[a](#tfn12-ol-0-0-10923){ref-type="table-fn"}^
  BMI \>30 kg/m^2^, n (%)                          22 (16.5)                                                  11 (18.3)                                                                                            11 (15.1)                                                  1.26 (0.51--3.16)          0.614
  High school, n (%)                               60 (45.1)                                                  27 (45.0)                                                                                            33 (45.2)                                                  0.99 (0.50--1.97)          0.981
  Graduation, n (%)                                15 (11.3)                                                  5 (8.3)                                                                                              10 (13.7)                                                  0.57 (0.18--1.78)          0.330
  Present smoker, n (%)                            12 (9.0)                                                   4 (6.7)                                                                                              8 (11.0)                                                   0.58 (0.17--2.03)          0.390
  Past smoker, n (%)                               53 (39.8)                                                  25 (41.7)                                                                                            28 (38.4)                                                  1.15 (0.57--2.30)          0.698
  Ever smoker, n (%)                               65 (48.9)                                                  29 (48.3)                                                                                            36 (49.3)                                                  0.96 (0.48--1.90)          0.910
  ≥20 cigarettes ever in all subjects, n (%)       40 (30.1)                                                  17 (28.3)                                                                                            23 (31.5)                                                  0.86 (0.41--1.81)          0.691
  Phototype number                                 2.4±0.7                                                    2.5±0.7                                                                                              2.3±0.6                                                    --                         0.146^[a](#tfn12-ol-0-0-10923){ref-type="table-fn"}^
  Phototype 1 and 2, n (%)                         77 (57.9)                                                  30 (50.0)                                                                                            47 (64.4)                                                  0.55 (0.28--1.11)          0.095^[g](#tfn18-ol-0-0-10923){ref-type="table-fn"}^
  Nevi \> 50, n (%)                                66 (49.6)                                                  35 (58.3)                                                                                            31 (42.5)                                                  1.90 (0.95--3.79)          0.069^[g](#tfn18-ol-0-0-10923){ref-type="table-fn"}^
  Burns over 5, n (%)                              71 (53.4)                                                  32 (53.3)                                                                                            39 (53.4)                                                  1.00 (0.50--1.98)          0.992
  NMetM, n (%)                                     72 (54.1)                                                  34 (56.7)                                                                                            38 (52.1)                                                  1.20 (0.61--2.39)          0.595
  Stage I, n (%)                                   52 (39.1)                                                  24 (40.0)                                                                                            28 (38.4)                                                  1.07 (0.53--2.16)          0.847
  Stage II, n (%)                                  19 (14.3)                                                  9 (15.0)                                                                                             10 (13.7)                                                  1.11 (0.42--2.94)          0.831
  Stage III, n (%)                                 38 (28.6)                                                  19 (31.7)                                                                                            19 (26.0)                                                  1.32 (0.62--2.80)          0.474
  Stage IV, n (%)                                  24 (18.0)                                                  8 (13.3)                                                                                             16 (21.9)                                                  0.55 (0.22--1.39)          0.200
  Trunk, n (%)                                     75 (56.4)                                                  36 (60.0)                                                                                            39 (53.4)                                                  1.31 (0.65--2.61)          0.447
  Upper limb, n (%)                                9 (6.8)                                                    5 (8.3)                                                                                              4 (5.5)                                                    1.57 (0.40--6.12)          0.731
  Lower limb, n (%)                                28 (21.1)                                                  11 (18.3)                                                                                            17 (23.3)                                                  0.74 (0.32--1.73)          0.486
  Hands/feet, n (%)                                8 (6.0)                                                    3 (5.0)                                                                                              5 (6.8)                                                    0.72 (0.16--3.13)          0.729
  Head/neck, n (%)                                 13 (9.8)                                                   5 (8.3)                                                                                              8 (11.0)                                                   0.74 (0.23--2.39)          0.612
  Superficial spreading, n (%)                     70 (52.6)                                                  31 (51.7)                                                                                            39 (53.4)                                                  0.93 (0.47--1.85)          0.840
  Nodular, n (%)                                   45 (33.8)                                                  23 (38.3)                                                                                            22 (30.1)                                                  1.44 (0.70--2.96)          0.320
  Acral lentiginous, n (%)                         5 (3.8)                                                    1 (1.7)                                                                                              4 (5.5)                                                    0.29 (0.03--2.69)          0.378
  Lentigo maligna, n (%)                           2 (1.5)                                                    0 (−)b                                                                                               2 (2.7)                                                    0.97 (0.94--1.01)          0.501
  Spitzoide, n (%)                                 5 (3.8)                                                    4 (6.7)                                                                                              1 (1.4)                                                    5.14 (0.56--47.3)          0.174
  Others, n (%)                                    9 (6.8)                                                    3 (5.0)                                                                                              6 (8.2)                                                    0.59 (0.14--2.46)          0.512
  Breslow thickness, mm, mean ± SD                 2.05±1.85                                                  2.17±2.12                                                                                            1.95±1.61                                                  --                         0.871^[a](#tfn12-ol-0-0-10923){ref-type="table-fn"}^
  Clark I, n (%)                                   2 (1.5)^[c](#tfn14-ol-0-0-10923){ref-type="table-fn"}^     0 (−)^[b](#tfn13-ol-0-0-10923){ref-type="table-fn"},[d](#tfn15-ol-0-0-10923){ref-type="table-fn"}^   2 (2.8)                                                    0.97 (0.93--1.01)          0.501
  Clark II, n (%)                                  32 (24.4)^[c](#tfn14-ol-0-0-10923){ref-type="table-fn"}^   15 (25.4)^[d](#tfn15-ol-0-0-10923){ref-type="table-fn"}^                                             17 (23.6)^[e](#tfn16-ol-0-0-10923){ref-type="table-fn"}^   1.10 (0.50--2.45)          0.810
  Clark III, n (%)                                 24 (18.3)^[c](#tfn14-ol-0-0-10923){ref-type="table-fn"}^   9 (15.3)^[d](#tfn15-ol-0-0-10923){ref-type="table-fn"}^                                              15 (20.8)^[e](#tfn16-ol-0-0-10923){ref-type="table-fn"}^   0.68 (0.27--1.70)          0.411
  Clark IV, n (%)                                  67 (51.1)^[c](#tfn14-ol-0-0-10923){ref-type="table-fn"}^   33 (55.9)^[d](#tfn15-ol-0-0-10923){ref-type="table-fn"}^                                             34 (47.2)^[e](#tfn16-ol-0-0-10923){ref-type="table-fn"}^   1.42 (0.71--2.83)          0.321
  Clark V, n (%)                                   4 (3.1)^[c](#tfn14-ol-0-0-10923){ref-type="table-fn"}^     1 (1.7)^[d](#tfn15-ol-0-0-10923){ref-type="table-fn"}^                                               3 (4.2)e                                                   0.40 (0.04--3.92)          0.627
  Ulceration, n (%)                                51 (38.3)                                                  26 (43.3)                                                                                            25 (34.2)                                                  1.47 (0.73--2.97)          0.284
  Mitosis \>1, n (%)                               83 (63.4)^[c](#tfn14-ol-0-0-10923){ref-type="table-fn"}^   39 (66.1)^[d](#tfn15-ol-0-0-10923){ref-type="table-fn"}^                                             44 (61.1)^[e](#tfn16-ol-0-0-10923){ref-type="table-fn"}^   1.24 (0.60--2.54)          0.555
  Regression, n (%)                                20 (15.3)^[c](#tfn14-ol-0-0-10923){ref-type="table-fn"}^   9 (15.3)^[d](#tfn15-ol-0-0-10923){ref-type="table-fn"}^                                              11 (15.3)^[e](#tfn16-ol-0-0-10923){ref-type="table-fn"}^   1.00 (0.38--2.60)          0.997
  Brisk positive TILs, n (%)                       38 (29.0)^[c](#tfn14-ol-0-0-10923){ref-type="table-fn"}^   17 (28.8)^[d](#tfn15-ol-0-0-10923){ref-type="table-fn"}^                                             21 (29.2)^[e](#tfn16-ol-0-0-10923){ref-type="table-fn"}^   0.98 (0.46--2.10)          0.965
  Non-brisk TILs, n (%)                            47 (35.9)^[c](#tfn14-ol-0-0-10923){ref-type="table-fn"}^   25 (42.4)^[d](#tfn15-ol-0-0-10923){ref-type="table-fn"}^                                             22 (30.6)^[e](#tfn16-ol-0-0-10923){ref-type="table-fn"}^   1.67 (0.81--3.43)          0.161
  TILs absence, n (%)                              45 (34.4)^[c](#tfn14-ol-0-0-10923){ref-type="table-fn"}^   17 (28.8)^[d](#tfn15-ol-0-0-10923){ref-type="table-fn"}^                                             28 (38.9)^[e](#tfn16-ol-0-0-10923){ref-type="table-fn"}^   0.64 (0.30--1.33)          0.227
  Microsatellitosis, n (%)                         5 (3.8)^[c](#tfn14-ol-0-0-10923){ref-type="table-fn"}^     2 (3.4)^[d](#tfn15-ol-0-0-10923){ref-type="table-fn"}^                                               3 (4.2)^[e](#tfn16-ol-0-0-10923){ref-type="table-fn"}^     0.81 (0.13--5.00)          1.000
  Epithelioid variant, n (%)                       37 (28.0)^[f](#tfn17-ol-0-0-10923){ref-type="table-fn"}^   14 (23.3)                                                                                            23 (31.9)^[e](#tfn16-ol-0-0-10923){ref-type="table-fn"}^   0.65 (0.30--1.41)          0.273
  Fusate variant, n (%)                            13 (9.8)^[f](#tfn17-ol-0-0-10923){ref-type="table-fn"}^    6 (10.0)                                                                                             7 (9.7)^[e](#tfn16-ol-0-0-10923){ref-type="table-fn"}^     1.03 (0.33--3.25)          0.957
  Small cell variant, n (%)                        2 (1.5)^[f](#tfn17-ol-0-0-10923){ref-type="table-fn"}^     0 (−)^[b](#tfn13-ol-0-0-10923){ref-type="table-fn"}^                                                 2 (2.8)^[e](#tfn16-ol-0-0-10923){ref-type="table-fn"}^     0.97 (0.93--1.01)          0.500
  More than 1 melanoma, n (%)                      20 (15.0)                                                  10 (16.7)                                                                                            10 (13.7)                                                  1.26 (0.49--3.26)          0.634
  Additional non-melanoma skin cancer, n (%)       22 (16.5)                                                  7 (11.7)                                                                                             15 (20.5)                                                  0.51 (0.19--1.35)          0.170
  Additional non-skin cancer, n (%)                29 (21.8)                                                  11 (18.3)                                                                                            18 (24.7)                                                  0.69 (0.29--1.59)          0.379
  Concurrent thyroid disease, n (%)                16 (12.0)                                                  8 (13.3)                                                                                             8 (11.0)                                                   1.25 (0.44--3.56)          0.675
  Melanoma familiarity, n (%)                      18 (13.5)                                                  10 (16.7)                                                                                            8 (11.0)                                                   1.62 (0.60--4.42)          0.338

Two-tailed Mann-Whitney *U*-test.

Uncountable because the group contained no subjects.

Data were available for 131 patients.

Data were available for 59 patients.

Data were available for 72 patients.

Data were available for 132 patients.

Significant tendencies. BMI, body mass index; FVG, Friuli Venezia-Giulia; *IL-1RN*, interleukin-1 receptor antagonist gene; OR, odds ratio; TILs, tumor-infiltrating lymphocytes; VNTR, variable number tandem repeat.
